ViraCyte Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Houston TX United States (2013)
Status: Acquired by ElevateBio (2019)

Organization Overview

First Clinical Trial
2013
NCT01570283
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Legacy Healthcare SA

Active Ingredients

Drugs in Phase 3 Trials (1)

cyclosporine (sandimmune) (1 trial)

Drugs in Phase 2 Trials (2)

finasteride (Proscar) (1 trial)

multi-virus-specific cytotoxic t lymphocytes (1 trial)

Drugs in Phase 1 Trials (1)

Posoleucel (viralym-a) (3 trials)

Drugs in Other Trials (1)

multivirus specific t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoviridae Infections (Phase 2)

Alopecia (Phase 3)

Alopecia Areata (Phase 3)

Cytomegalovirus Infections (Phase 1)

Infections (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5